Atea Pharmaceuticals (AVIR) Other financing activities (2021 - 2026)

Atea Pharmaceuticals' Other financing activities history runs 6 years deep, the most recent figure standing at $132000.0 for Q1 2026.

• On a quarterly basis, Other financing activities fell 4.35% year-over-year to $132000.0 in Q1 2026; TTM through Mar 2026 was $338000.0, a 32.55% increase from a year earlier, with the FY2025 full-year figure at $201000.0, down 24.72% from the prior year.
• Other financing activities fell to $132000.0 in Q1 2026 per AVIR's latest filing, from $143000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $223000.0 in Q1 2022 and bottomed at $63000.0 in Q3 2025.
• The 5-year median for Other financing activities is $139000.0 (2022), against an average of $136300.0.
• Across the five-year window, Other financing activities sank 82.39% in 2022 and grew 27.17% in 2024, its largest moves.
• Year by year, Other financing activities stood at $140000.0 in 2022, then plunged by 34.29% to $92000.0 in 2023, then rose by 27.17% to $117000.0 in 2024, then grew by 22.22% to $143000.0 in 2025, then dropped by 7.69% to $132000.0 in 2026.
• Per Business Quant, the three latest AVIR Other financing activities figures stand at $132000.0 (Q1 2026), $143000.0 (Q4 2025), and $63000.0 (Q3 2025).